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lymphomaAbstract Background: Occult hepatitis B infection (OBI) is characterized by negative hepatitis B
surface antigen (HBsAg) and detectable hepatitis B virus (HBV)-DNA in the liver and/or serum,
with or without hepatitis B core antibody (anti-HBc). Anti-HBc is the most sensitive marker of pre-
vious HBV. HBV reactivation in patients under immunosuppressive treatment is life-threatening,
occurring in both overt and occult HBV especially in hematological malignancies.
Aim of the work: To evaluate the prevalence and chemotherapy-induced reactivation of OBI
among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma (DLBCL)
patients and to determine the signiﬁcance of anti-HBc screening among this group of patients
before receiving chemotherapy.
Patients and methods: This cross-sectional study included 72 DLBCL patients negative for HBsAg,
HBsAb and hepatitis C virus antibodies (anti-HCV). Patients were subjected to investigations
including anti-HBc. All patients underwent alanine transaminase (ALT) monitoring before each
cycle of chemotherapy and monthly for 12 months after the end of chemotherapy. Patients with
suspected OBI were tested for HBV-DNA using real-time polymerase chain reaction (PCR).
Results: Anti-HBc was detected in 10 of 72 HBsAg negative sera (13.89%) (95% conﬁdence
interval 6.9–22.2%). Five of the 10 anti-HBc positive patients in this study had OBI reactivation.
12 T.A. Elbedewy et al.Conclusion: The study concluded that anti-HBc screening is mandatory before chemotherapy.
HBsAg-negative/anti-HBc-positive patients should be closely observed for signs of HBV reactiva-
tion through the regular monitoring of ALT. Prophylaxis lamivudine is recommended for
anti-HBc positive patients before chemotherapy.
ª 2015 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Hepatitis B virus (HBV) infection is a major health problem,
affecting about 2 billion people worldwide despite of the effec-
tive vaccination. There are 350 million HBV carriers world-
wide and about one million die annually from HBV-related
liver disease [1]. The prevalence of HBV infection varies in
different parts of the world (<1–15%) [2]. Intermediate
endemicity of HBV infection had been recorded in Egypt [3].
Occult HBV infection (OBI) is characterized by negative
serum hepatitis B surface antigen (HBsAg) and detectable
HBV-DNA in the liver and/or serum, with or without hepatitis
B core antibody (anti-HBc) [4]. Anti-HBc is the most sensitive
marker of previous HBV infection [5]. Anti-HBc is the ﬁrst
antibody to appear and present in all different phases of
HBV. Anti-HBc may persist longer than hepatitis B surface
antibody (anti-HBs) or hepatitis B envelope antibody (anti-
HBe); however, it is not protective. Anti-HBc IgM may help
in the diagnosis of the acute HBV and also during ﬂares [6].
HBV reactivation in patients under immunosuppressive
treatment is life-threatening occurring in both overt and occult
HBV infection [7,8]. The risk of HBV reactivation is high with
marked immunosuppression, especially in hematological
malignancies chemotherapy (21–67%), bone marrow trans-
plantation and monoclonal antibody therapy [9,10]. Under
these conditions, HBV reactivation is associated with a mor-
tality rate close to 20%, due to hepatic failure [11].
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon non-Hodgkin’s lymphoma (NHL). Standard treatment
for newly diagnosed DLBCL is anthracycline-based che-
motherapy regimen, usually cyclophosphamide, doxorubicin,
vincristine, and prednisone with or without rituximab [12].
Hence, the aim of this study was to evaluate the prevalence
and chemotherapy-induced reactivation of OBI among hepati-
tis B surface antigen negative patients with diffuse large B-cell
lymphoma (DLBCL) patients and to determine the sig-
niﬁcance of anti-HBc screening among this group of patients
before receiving chemotherapy.Patients and methods
This cross-sectional study included 72 patients with diffuse
large B-cell lymphoma (DLBCL) before receiving chemother-
apy. Patients of this study were selected from the Hematology
Unit, Internal Medicine Department, Faculty of Medicine,
Tanta University and Tanta Cancer Center from May 2012
to October 2014. All patients included were negative for
HBsAg, HBsAb and antibody for hepatitis C (anti-HCV). This
study was conducted in accordance with the guidelines of the
declaration of Helsinki 1975 and its subsequent amendments
(1983). Participation in the study was voluntary after aninformed written consent was obtained from the patients prior
to the study.
All the patients were asked questions regarding age, sex,
blood transfusion, past surgical procedures, intravenous drug
abuse, jaundice, admission to fever hospital, and history of
HBV vaccination.
Patients with recent jaundice, recent hospitalization due to
fever, pregnancy, recent delivery less than 12 weeks or close
contact with a patient suffering from hepatitis in the last
6 months were excluded. Exclusion criteria also included acute
or chronic HBV infection as marked by positive HBsAg.
Patients with HCV, human immunodeﬁciency virus (HIV),
any hematological malignancy other than DLBCL or previous
immunosuppressive treatments of any kind were also excluded.
Prior to start of the DLBCL treatment every patient under-
went full history talking, complete physical examination, rou-
tine biochemistry assays including alanine transaminase (ALT)
and aspartate transaminase (AST).
Diffuse large B-cell lymphoma (DLBCL) was diagnosed
based on histopathological examination of lymph nodes and/
or extranodal tissue biopsy specimen according to the Revised
European-American Lymphoma (REAL) classiﬁcation criteria
revised by Harris [13]. Patients were staged according to the
Ann Arbor staging system with Cotswolds modiﬁcations [14].
Ann Arbor staging was determined for all patients at the onset
of DLBCL by physical examination, computed tomography
scan (abdomen & pelvis, chest and neck) and bone marrow
examination. The International Prognostic Index (IPI) was
used for determining the prognosis of DLBCL [15]. Cheson’s
criteria were used to deﬁne the response to chemotherapy [16].
The standard protocol chemotherapy for DLBCL used in
this study was CHOP [intravenous cyclophosphamide 750 mg/m2,
doxorubicin 50 mg/m2, and vincristine 1.4 mg/m2 (maximum
dose: 2 mg) on day 1 and oral prednisone 100 mg/day on days
1–5] every 3 weeks for (6–8) cycles [17]. For patients with
relapsed or progressed disease second line therapy ICE [24 h
intravenous infusion ifosfamide 5000 mg/m2 on day 2, intra-
venous carboplatin using the Calvert formula with maximum
800 mg on day 2 and intravenous etoposide 100 mg/m2 on day
1–3] every 14 days or CEOP [intravenous cyclophosphamide
750 mg/m2 on day 1, intravenous etoposide 50 mg/m2 on day
1 and 100 mg/m2 orally on day 2 and 3, intravenous vincristine
1.4 mg/m2 IV (maximum dose: 2 mg) on day 1 and orally pred-
nisone 100 mg/m2 on day 1–10) every 3 weeks for patients candi-
date andnoncandidate for highdose therapy respectively [18,19].
All patients underwent total bilirubin and ALT monitoring
during therapy before each cycle of chemotherapy and month-
ly for 12 months after the end of chemotherapy. If the patient
experienced an ALT elevation more than threefold above the
upper normal value, complete investigations including HBsAg,
HBV-DNA levels, anti-HBc IgM, IgM hepatitis A virus anti-
body (anti-HAV) and HCV-RNA were performed to prove
Table 1 Demographical characteristics of the study
population.
Variables Number (%)
Diﬀuse large B-cell
lymphoma stages
I 9 (12.5%)
II 25 (34.72%)
III 31 (43.06%)
IV 7 (9.72%)
International Prognostic Index Low 7 (9.72%)
Low/intermediate 8 (11.11%)
Intermediate/high 42 (58.33%)
High 15 (20.83%)
Cheson’s criteria for response Complete Remission 49 (68.06%)
Partial remission 13 (18.06%)
Relapse or progression 10 (13.88%)
Fate of all patients Alive 64 (88.89%)
Died 8 (11.11%)
Chemotherapy-Induced OBI reactivation 13OBI reactivation and exclude other causes of hepatitis. When
OBI reactivation occurred, lamivudine therapy was promptly
started at the standard dosage (100 mg orally once daily).
ALT monitoring was performed every 2 weeks and complete
liver functional tests including HBV-DNA quantitative assay
were performed monthly.
Deﬁnition of OBI reactivation
Hepatitis was deﬁned as a threefold or greater increase in
serum ALT levels that exceeded the reference range (normal
value, <42 IU/L) or an absolute increase of ALT to more than
100 IU/L. Hepatitis was attributed to OBI reactivation when
there was evidence of HBsAg seroreversion (the reappearance
of HBsAg) with an increase in HBV-DNA levels when com-
pared with baseline HBV-DNA levels (>2000 IU/mL), in the
absence of history, clinical or laboratory features of all other
possible etiological factors of hepatitis [20].
Serological assays
Ten milliliters of blood were collected from each patient in a
sterile, capped tube (before chemotherapy and after OBI reac-
tivation). Blood was centrifuged and serum stored at 80 C
until it was needed for testing.
Another portion of blood was collected in vacutainer tubes
containing citrate to separate plasma used for the assay of pro-
thrombin time and activity.
All serum samples were tested for serum alanine transami-
nase (ALT; upper normal limit UNL 42 IU/L), aspartate trans-
aminase (AST; UNL 37 IU/L) and total bilirubin (UNL 1
mg/dl) using chemistry autoanalyzer (Synchron CX5, Beckman
Instrument Inc., Scientiﬁc Instrument Division, Fullerton, CA).
Hepatitis B markers (hepatitis B core antibodies, hepatitis
B surface antigen and hepatitis B surface antibody) were
detected by electrochemiluminescence immunoassay on Roche
Elecsys 201014. Antibodies to HCV (anti-HCV) were detected
using a standard third generation ELISA test (Murex anti-
HCV, version 4.0). HAV was detected by commercial enzyme
immunoassays (Cobas Core Anti-HAV IgM EIA, Roche
Diagnostics GmbH, Mannheim, Germany). All procedures
were performed according to the manufacturers’ instructions.
Detection of HBV-DNA and HCV-RNA: [21]
DNA was extracted from patient’s serum with OBI reactiva-
tion and stored serum for these patients. Samples from each
patient were tested for HBV-DNA using highly sensitive and
speciﬁc real-time PCR. HBV-DNA was extracted from
850 lL of plasma by the Cobas AmpliPrep instrument. The
Cobas TaqMan 48 analyzer was used for automated real-time
PCR ampliﬁcation and detection of PCR products.
HBV-DNA levels were expressed in IU/mL. The HBV detec-
tion limit was 12 IU/mL.
Patients with OBI reactivation, HCV-RNA was carried out
using real time PCR. The HCV detection limit was 15 IU/mL.
Statistical analysis
The collected data were analyzed using SPSS version 17
software (SPSS Inc, Chicago, ILL Company). Comparisonof continuous data between two groups was made by using
Mann–Whitney test for non-parametric data. Fisher’s exact
test was used for comparison between categorical data.
Survival analysis was done using Kaplan–Meier method and
comparison between two survival curves was done using
log-rank test. The accepted level of signiﬁcance in this work
was stated at 0.05 (P< 0.05 was considered signiﬁcant).
Results
Patient characteristics
This study included 72 patients with diffuse large B-cell
lymphoma (DLBCL) before receiving chemotherapy; their
ages ranged from 23 to 67 years (mean 50.79 ± 9.381 years),
51 were males (70.83%) while the other 21 were females
(29.17%). All patients did not receive HBV vaccination before.
Fifteen patients (20.83%) had history of blood transfusion and
24 patients (33.33%) had history of surgical operations. Other
demographical characteristics of the study population are
shown in Table 1.
All patients were followed up for 18 months from the start
of chemotherapy with median 18 months (range 7–18 months)
due to death of 2 patients due to OBI reactivation at the 10th
and 11th months from the start of chemotherapy and death of
6 patients due to tumor progression at the 7th, 8th, 9th, 12th,
13th and 15th months from the start of chemotherapy.
HBV serology before receiving chemotherapy
Among the 72 HBsAg negative sera, anti-HBc was detected in
10 of 72 (13.89%) (95% conﬁdence interval 6.9–22.2%). All
the anti-HBc positive sera were anti-HBs negative.
Consequences of HBV serology after chemotherapy
After the initiation of systemic chemotherapy, examination of
the HBV serology revealed that 5 of the 10 anti-HBc-positive
patients (50%) (6.94% as regarding all patients) became sero-
logically positive for the HBsAg with a marked increase in
ALT levels exceeding threefold which was molecularly
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14 T.A. Elbedewy et al.detectable for the HBV-DNA (OBI reactivation) as shown in
Table 2.
Characteristics of occult HBV reactivated patients
Five of the 72 patients (6.94%) treated for DLBCL manifested
with OBI reactivation. All of the ﬁve patients had OBI reacti-
vation after the completion of all their chemotherapy cycles
with mean time 9.4 ± 1.517 months; range 7–11 months after
chemotherapy was started. Patients with OBI had mean
baseline ALT (35 ± 6.595; range 29–45 U/L), mean ALT after
reactivation (1092.2 ± 533.22; range 450–1776 U/L),
mean HBV-DNA after reactivation (84.6 ± 26.71; range
48–121 · 104 IU/mL), mean total bilirubin after reactivation
(5.42 ± 3.419; range 2.2–9.4 mg/dl), and mean prothrombin
activity after reactivation (52.8 ± 15.531; range 36–72%). All
of the ﬁve patients had negative result of Anti-HAV-IgM
and HCV-RNA. All of them received lamivudine therapy
but 2 of them died due to liver failure and the other three
patients had been recovered. Characteristics of occult HBV
reactivated patients are shown in Table 2.
Comparison between patients with OBI reactivation and
patients without OBI reactivation in Anti-HBc positive
patients as regard different variables were shown in Table 3.
Survival analysis was done using Kaplan–Meier method
and comparison between two survival curves was done using
log-rank test which revealed insigniﬁcant difference between
patients with negative anti-HBc and patients with positive
anti-HBc, also insigniﬁcant difference between patients with
or without OBI reactivation as regard survival rate (Table 4
and Figs. 1, 2).
Discussion
The natural course of HBV infection is determined by the
interplay between virus replication and host’s immune
response [22]. Chemotherapy may lead to an increase in virus
replication and infection of more hepatocytes in the absence of
an active host immune response [23].
Chemotherapy decreases the host’s immune response, so a
period of time is necessary for the immune system to begin
attacking the hepatocytes, where a massive replication of
HBV has taken place [24]. For this reason, HBV reactivation
often manifests between cycles of chemotherapy or at the
end of therapy after the recovery of the host immune system
[25]. The reported interval ranges from 1 to 9 months from ini-
tiation of chemotherapy. HBV reactivation can easily be
missed, particularly in early stages, when salvage anti-viral
therapy could be lifesaving [26]. Since OBI reactivation is
asymptomatic and transient, regular frequent monitoring of
ALT is essential although there is no guideline regarding fre-
quency of testing [27].
Prophylaxis of HBsAg-negative/anti-HBc-positive patients
undergoing highly immunosuppressive treatment for hemato-
logical malignancies is not conclusive and not routinely recom-
mended [28,29]. Although the data of a recent meta-analysis
recommended prophylaxis therapy for patients receiving ritux-
imab-based chemotherapy due to increases the risk of OBI
reactivation [30].
In Egypt, testing for the presence of HBsAg is the initial
diagnostic examination used to determine HBV infection.
Table 3 Comparison between patients with OBI reactivation and patients without OBI reactivation in anti-HBc positive patients as
regards different variables.
Variables Patients with OBI
reactivation (N= 5)
Patients without OBI
reactivation (N= 5)
P-value (signiﬁcance)
Age (years) (mean ± SD) 53 ± 9.06 51.2 ± 8.11 0.75 (NS)
Sex Male (N) (%) 3 (60%) 4 (80%) 1.00 (NS)
Female (N) (%) 2 (40%) 1 (20%)
Stage II (N) (%) 1 (20%) 2 (40%) 1.00 (NS)
III (N) (%) 4 (80%) 3 (60%)
IPI L/I (N) (%) 1 (20%) 1 (20%) 1.00 (NS)
I/H (N) (%) 4 (80%) 4 (80%)
Response CR (N) (%) 5 (100%) 4 (80%) 1.00 (NS)
PR (N) (%) Zero (0%) 1 (20%)
Fate Alive (N) (%) 3 (60%) 5 (100%) 0.44 (NS)
Dead (N) (%) 2 (40%) Zero (0%)
Anti-HBc, hepatitis B core antibody; CR, complete remission; I/H, intermediate/high; IPI, International Prognostic Index; L/I, intermediate/
high; N, number; NS, non-signiﬁcant; OBI, occult hepatitis B infection; PR, partial remission.
Table 4 Overall survival probability for different groups of patients.
Number of
patients
Events
(N)
Censored
(N) (%)
Median survival
(years)
Range
(years)
Statistic test for equality
of survival distributions
(Log Rank)
Statistic df P-value
(signiﬁcance)
Patients with negative anti-HBc 62 6 56 (90.32%) 18 7–18 0.95 1 0.329 (NS)
Patients with positive anti-HBc 10 2 8 (80%) 18 10–18
Patients with OBI reactivation 5 2 3 (60%) 18 10–18 2.24 1 0.134 (NS)
Patients without OBI reactivation 5 0 5 (100%) Can’t be computed since
all patients are censored
Anti-HBc, hepatitis B core antibody; N, number; NS, non-signiﬁcant; OBI, occult hepatitis B infection.
Figure 1 Kaplan–Meier analysis of the overall survival probability in patients with positive and negative hepatitis B core antibody
(anti-HBc).
Chemotherapy-Induced OBI reactivation 15Anti-HBc was not used to as screening test to determine
previous exposure to the hepatitis B virus. Hence, the aim of
this study was to evaluate the prevalence and chemotherapy-induced reactivation of OBI among hepatitis B surface antigen
negative patients with diffuse large B-cell lymphoma (DLBCL)
patients and to determine the signiﬁcance of anti-HBc
Figure 2 Kaplan–Meier analysis of the overall survival probability in patients with or without occult hepatitis B infection (OBI)
reactivation.
16 T.A. Elbedewy et al.screening among this group of patients before receiving
chemotherapy.
Our study revealed that, among the 72 HBsAg negative sera
of patients with DLBCL, anti-HBc was detected in 10 of 72
(13.89%) (95% conﬁdence interval 6.9–22.2%). All the anti-
HBc positive sera were anti-HBs negative. After the initiation
of systemic chemotherapy, examination of the HBV serology
revealed that 5 of the 10 anti-HBc-positive patients (50%)
(6.94% as regarding all patients) became serologically positive
for the HBsAg with a marked increase in ALT levels exceeding
threefold which was molecularly detectable for the HBV-DNA
(OBI reactivation). All of the 5 patients had OBI reactivation
after the completion of all their chemotherapy cycles with
mean time 9.4 ± 1.517 months after chemotherapy start
(range 7–11 months). All of them received lamivudine therapy
but 2 of them died due liver cell failure and the other three
patients had been recovered.
Different studies had been done in patients with lymphoma
and other hematological malignancies for the incidence of OBI
and reactivation of OBI during and after different regimens of
chemotherapy. Different ﬁgures in OBI and reactivation of
OBI were reported, some were with our results and the others
were different.
In China, Hui et al. [31] estimated HBV reactivation inci-
dence in 244 HBsAg-negative lymphoma patients receiving
chemotherapy was 3.3% (8/244). All the 8 patients were sero-
positive for either anti-HBc or anti-HBs antibody. Also in
China, Yeo et al. [10] who made their study among 104
CD20+ DLBCL patients, found that 80 out of 104 were
HBsAg negative, 46 patients out of 104 (44.2%) were HBsAg
negative/anti-HBc positive; 25 of these patients were treated
with CHOP without HBV reactivation but among the other 21
patients who were treated with R-CHOP, ﬁve developed HBV
reactivation, including one patient who died of hepatic failure.
In Japan, Matsue et al. [32] conducted a retrospective study
on consecutive patients with CD20-positive B cell lymphoma
before and after rituximab-containing treatment. Five out of
230 patients negative for HBsAg (2.2%) experienced HBV
reactivation, representing an incidence of 8.9% of the anti-
HBc-positive patients. In Hong Kong, Cheung et al. [33]
included 47 lymphoma patients in their study, 10 out of 47(21%) had OBI. One of the 10 patients, showed virological
reactivation followed by biochemical reactivation without liver
cell failure where entecavir treatment was used. Regarding the
other nine OBI patients, their serum hepatitis B virus DNA
levels ﬂuctuated, but there was no associated biochemical
reactivation.
In Italy, a prospective observational study of patients with
hematological malignancies, Francisci et al. [34] reported the
incidence of HBV reactivation was 18%, which is close to that
detected in the present study. Also in Italy, Masarone et al. [35]
who study 498 patients with non Hodgkin’s lymphoma 40% of
patients were treated with monoclonal antibodies and 60%
without. Ninety-six patients (19.28%) were anti-HBc+,
HBsAg. HBV reactivation occurred in ten subjects of this
subgroup (10.42%). All of them were successfully treated with
lamivudine.
In Egypt, Elkady et al. [36] showed that 18 (34%) out of 53
HBsAg-negative Egyptian patients with hematologic malig-
nancies were found to be positive for anti-HBc. Five of the
53 (9.4%) patients with hematologic malignancies experienced
HBV reactivation. In Greece, Zachou et al. [37] retrospectively
evaluated the medical records of HBsAg negative patients who
suffered HBV reactivation after chemotherapy or immunosup-
pression and identiﬁed 14 patients with occult or resolved
infection. Twelve out of 14 patients were males. In 71.4% of
them the primary diagnosis was hematologic malignancy;
78.6% had received rituximab as part of the immunosuppres-
sive regimen. The median time from last chemotherapy sched-
ule till HBV reactivation for 10 out of 11 patients who received
rituximab was 3 (range 2–17) months. Three patients (21.4%)
deteriorated, manifesting ascites and hepatic encephalopathy
and 2 (14.3%) of them died due to liver failure.
In Taiwan, Hsu et al. [38] who made their study on 150
newly diagnosed lymphoma patients with resolved HBV infec-
tion who received rituximab-CHOP-based chemotherapy and
found that the incidence of HBV reactivation and HBV-related
hepatitis ﬂares was 10.4 and 6.4 per 100 person-year, respec-
tively and showed that severe HBV-related hepatitis occurred
in 4 patients, despite entecavir treatment.
The reasons for the difference in the incidence in OBI
reactivation among different studies remain to be elucidated.
Chemotherapy-Induced OBI reactivation 17However, immunosuppressive regimen, the intensity of treat-
ment, study size, studied population characters, geographic
differences in HBV prevalence, HBV genotypes, lack of a clear
deﬁnition of OBI reactivation and differences in sensitivity of
the methods used for detection of the virus genome may
account for these differences [39].
Our study is not without limitation; as it lacked examina-
tion of liver biopsy to certify that patients with anti-HBc and
having negative HBV-DNA had no occult HBV. Indeed, we
found it unethical to expose the patient to this aggressive tech-
nique without direct beneﬁt to them. Also, our study lacked
patients treated with the golden standard regimen (R-CHOP)
but we found it unethical to expose the patient to high inci-
dence of OBI reactivation without lamivudine prophylaxis
which may affect the result of this study.
Conclusion
The study concluded that anti-HBc screening is mandatory
before chemotherapy. HBsAg-negative/anti-HBc-positive
patients should be closely observed for signs of HBV reactiva-
tion through the regular monitoring of ALT. Prophylaxis
lamivudine is recommended for OBI before chemotherapy.
A wider study on large number of patients is recommended.
Also, HBV full genome ampliﬁcation and sequencing are rec-
ommended in further research to identify the most susceptible
HBV genome for HBV reactivation.
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